TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Cynata Therapeutics Limited ( (AU:CYP) ) is now available.
Cynata Therapeutics announced that its CEO, Dr. Kilian Kelly, will present at the Bioshares Biotech Summit in Hobart, focusing on the development of its Cymerus™ iPSC-derived MSC therapies and upcoming key milestones for the company. This presentation is significant as it highlights Cynata’s progress and strategic direction in the biotech sector, potentially influencing investor interest and market positioning.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage company specializing in stem cell and regenerative medicine. The company focuses on developing therapies using its proprietary Cymerus™ platform, which leverages induced pluripotent stem cells (iPSCs) to produce mesenchymal stem cells (MSCs) economically and at a commercial scale. This approach addresses the challenges of conventional MSC production, such as the need for multiple tissue donors and product inconsistency. Cynata has shown positive results in clinical trials for conditions like steroid-resistant acute graft versus host disease and diabetic foot ulcers, and is conducting further trials for various other diseases.
Average Trading Volume: 179,443
Technical Sentiment Signal: Sell
Current Market Cap: A$39.54M
Learn more about CYP stock on TipRanks’ Stock Analysis page.